Western Governors University
WGU D345 / NURS 6438 Psychopharmacology
Comprehensive Final OA Exam 2026-2027
Name: Student ID: ___________________ Date: ____________________
_________________________
Total Questions: 70 | Format: Multiple Choice | Select the BEST answer for each question.
Correct answers are highlighted in cyan with rationales.
I. Neurotransmitter Systems (Questions 1-10)
1. Which neurotransmitter is primarily implicated in the pathophysiology of major depressive disorder?
A. Gamma-aminobutyric acid (GABA)
B. Serotonin (5-HT)
C. Dopamine
D. Histamine
Rationale: Serotonin (5-HT) is the neurotransmitter most consistently implicated in the pathophysiology of major
depressive disorder, forming the basis for the monoamine hypothesis. SSRIs, which selectively enhance serotonergic
neurotransmission, are first-line pharmacotherapy. While dopamine and norepinephrine also play roles, serotonin
remains the primary target.
2. A patient with schizophrenia is prescribed a medication that blocks D2 receptors in the mesolimbic pathway.
What is the primary expected therapeutic effect?
A. Reduction of positive symptoms such as hallucinations
B. Improvement of negative symptoms such as anhedonia
C. Enhancement of cognitive function
D. Stabilization of mood fluctuations
Rationale: D2 receptor blockade in the mesolimbic pathway reduces positive symptoms of schizophrenia, including
hallucinations and delusions. This is the primary mechanism of both typical and atypical antipsychotics. Negative
symptoms and cognitive deficits are less responsive to D2 antagonism.
3. Which neurotransmitter system is the primary target of benzodiazepines in the treatment of anxiety disorders?
A. Serotonergic system
B. Dopaminergic system
C. GABAergic system
D. Noradrenergic system
Rationale: Benzodiazepines enhance GABA-A receptor activity by increasing the frequency of chloride channel
opening, producing anxiolytic, sedative, and muscle relaxant effects. This mechanism distinguishes them from
buspirone, which acts on serotonin receptors, and from beta-blockers, which target noradrenergic signaling.
4. The dopaminergic pathway responsible for the extrapyramidal side effects (EPS) of antipsychotic medications
is the:
A. Mesolimbic pathway
B. Mesocortical pathway
1
, C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Rationale: The nigrostriatal pathway regulates motor function, and D2 blockade in this pathway produces
extrapyramidal symptoms such as dystonia, akathisia, parkinsonism, and tardive dyskinesia. The mesolimbic pathway
is associated with antipsychotic efficacy, while the tuberoinfundibular pathway affects prolactin secretion.
5. Norepinephrine reuptake inhibition in the prefrontal cortex is the primary mechanism of which medication
class?
A. Selective serotonin reuptake inhibitors (SSRIs)
B. Serotonin-norepinephrine reuptake inhibitors (SNRIs)
C. Typical antipsychotics
D. Benzodiazepines
Rationale: SNRIs (e.g., venlafaxine, duloxetine) inhibit the reuptake of both serotonin and norepinephrine.
Norepinephrine reuptake inhibition in the prefrontal cortex contributes to improved concentration, energy, and mood
regulation. SSRIs selectively target serotonin only.
6. Which neurotransmitter is most closely associated with the rewarding effects of substances and the
pathophysiology of addiction?
A. Acetylcholine
B. Serotonin
C. Dopamine
D. GABA
Rationale: The mesolimbic dopamine pathway mediates reward and reinforcement, and dysregulation of this system
is central to the pathophysiology of substance use disorders. All substances of abuse directly or indirectly increase
dopaminergic signaling in the nucleus accumbens.
7. Glutamate hypofunction at the NMDA receptor has been proposed as a contributing factor in which
psychiatric condition?
A. Generalized anxiety disorder
B. Schizophrenia
C. Major depressive disorder
D. Obsessive-compulsive disorder
Rationale: The NMDA receptor hypofunction hypothesis of schizophrenia posits that reduced glutamatergic signaling
contributes to both positive and negative symptoms. This theory is supported by the psychotomimetic effects of NMDA
antagonists such as ketamine and PCP.
8. A PMHNP is educating a patient about how SSRIs work. Which explanation is most accurate?
A. "SSRIs increase the release of serotonin from presynaptic terminals."
B. "SSRIs block serotonin receptors postsynaptically to reduce anxiety."
C. "SSRIs block the reuptake of serotonin, increasing its availability in the synaptic cleft."
D. "SSRIs directly stimulate serotonin production in the raphe nuclei."
Rationale: SSRIs selectively inhibit the serotonin transporter (SERT), blocking reuptake of serotonin from the
synaptic cleft back into the presynaptic neuron. This increases serotonin availability at postsynaptic receptors. They
do not increase serotonin release, block postsynaptic receptors, or stimulate serotonin production.
2
, 9. Which neurotransmitter pathway, when blocked, results in elevated prolactin levels?
A. Nigrostriatal pathway
B. Mesolimbic pathway
C. Tuberoinfundibular pathway
D. Mesocortical pathway
Rationale: The tuberoinfundibular pathway normally exerts tonic dopaminergic inhibition on prolactin release from
the anterior pituitary. D2 receptor blockade in this pathway (by antipsychotics) removes this inhibition, leading to
hyperprolactinemia, which may cause galactorrhea, amenorrhea, and sexual dysfunction.
10. Acetylcholinesterase inhibitors are primarily used in the treatment of which condition?
A. Schizophrenia
B. Alzheimer's disease
C. Major depressive disorder
D. Bipolar disorder
Rationale: Acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) increase acetylcholine
availability in the brain by preventing its enzymatic breakdown. They are FDA-approved for symptomatic treatment of
Alzheimer's disease and are the mainstay of cognitive enhancement in dementia.
II. Pharmacokinetics & Pharmacodynamics (Questions 11-18)
11. A medication with a short half-life of 4 hours will reach steady-state concentration in approximately how
long?
A. 4 hours
B. 8 hours
C. 20 hours
D. 40 hours
Rationale: Steady-state concentration is achieved in approximately 4-5 half-lives. For a medication with a 4-hour
half-life, steady state is reached in 16-20 hours (4 x 4 = 16 to 5 x 4 = 20). This principle is critical for determining
when to assess therapeutic response and adjust dosing.
12. Which factor most significantly increases the bioavailability of a medication administered orally?
A. High first-pass metabolism
B. Administration with a high-fat meal
C. Extensive plasma protein binding
D. High water solubility
Rationale: Administration with a high-fat meal can increase the bioavailability of lipophilic medications by
enhancing their absorption through improved solubility in the gastrointestinal tract. First-pass metabolism
REDUCES bioavailability. Plasma protein binding affects distribution, not absorption. Water solubility alone does
not determine bioavailability.
13. A patient with hepatic cirrhosis is prescribed a psychotropic medication that undergoes extensive hepatic
metabolism. Which pharmacokinetic change is most expected?
A. Decreased volume of distribution
B. Increased clearance rate
3
WGU D345 / NURS 6438 Psychopharmacology
Comprehensive Final OA Exam 2026-2027
Name: Student ID: ___________________ Date: ____________________
_________________________
Total Questions: 70 | Format: Multiple Choice | Select the BEST answer for each question.
Correct answers are highlighted in cyan with rationales.
I. Neurotransmitter Systems (Questions 1-10)
1. Which neurotransmitter is primarily implicated in the pathophysiology of major depressive disorder?
A. Gamma-aminobutyric acid (GABA)
B. Serotonin (5-HT)
C. Dopamine
D. Histamine
Rationale: Serotonin (5-HT) is the neurotransmitter most consistently implicated in the pathophysiology of major
depressive disorder, forming the basis for the monoamine hypothesis. SSRIs, which selectively enhance serotonergic
neurotransmission, are first-line pharmacotherapy. While dopamine and norepinephrine also play roles, serotonin
remains the primary target.
2. A patient with schizophrenia is prescribed a medication that blocks D2 receptors in the mesolimbic pathway.
What is the primary expected therapeutic effect?
A. Reduction of positive symptoms such as hallucinations
B. Improvement of negative symptoms such as anhedonia
C. Enhancement of cognitive function
D. Stabilization of mood fluctuations
Rationale: D2 receptor blockade in the mesolimbic pathway reduces positive symptoms of schizophrenia, including
hallucinations and delusions. This is the primary mechanism of both typical and atypical antipsychotics. Negative
symptoms and cognitive deficits are less responsive to D2 antagonism.
3. Which neurotransmitter system is the primary target of benzodiazepines in the treatment of anxiety disorders?
A. Serotonergic system
B. Dopaminergic system
C. GABAergic system
D. Noradrenergic system
Rationale: Benzodiazepines enhance GABA-A receptor activity by increasing the frequency of chloride channel
opening, producing anxiolytic, sedative, and muscle relaxant effects. This mechanism distinguishes them from
buspirone, which acts on serotonin receptors, and from beta-blockers, which target noradrenergic signaling.
4. The dopaminergic pathway responsible for the extrapyramidal side effects (EPS) of antipsychotic medications
is the:
A. Mesolimbic pathway
B. Mesocortical pathway
1
, C. Nigrostriatal pathway
D. Tuberoinfundibular pathway
Rationale: The nigrostriatal pathway regulates motor function, and D2 blockade in this pathway produces
extrapyramidal symptoms such as dystonia, akathisia, parkinsonism, and tardive dyskinesia. The mesolimbic pathway
is associated with antipsychotic efficacy, while the tuberoinfundibular pathway affects prolactin secretion.
5. Norepinephrine reuptake inhibition in the prefrontal cortex is the primary mechanism of which medication
class?
A. Selective serotonin reuptake inhibitors (SSRIs)
B. Serotonin-norepinephrine reuptake inhibitors (SNRIs)
C. Typical antipsychotics
D. Benzodiazepines
Rationale: SNRIs (e.g., venlafaxine, duloxetine) inhibit the reuptake of both serotonin and norepinephrine.
Norepinephrine reuptake inhibition in the prefrontal cortex contributes to improved concentration, energy, and mood
regulation. SSRIs selectively target serotonin only.
6. Which neurotransmitter is most closely associated with the rewarding effects of substances and the
pathophysiology of addiction?
A. Acetylcholine
B. Serotonin
C. Dopamine
D. GABA
Rationale: The mesolimbic dopamine pathway mediates reward and reinforcement, and dysregulation of this system
is central to the pathophysiology of substance use disorders. All substances of abuse directly or indirectly increase
dopaminergic signaling in the nucleus accumbens.
7. Glutamate hypofunction at the NMDA receptor has been proposed as a contributing factor in which
psychiatric condition?
A. Generalized anxiety disorder
B. Schizophrenia
C. Major depressive disorder
D. Obsessive-compulsive disorder
Rationale: The NMDA receptor hypofunction hypothesis of schizophrenia posits that reduced glutamatergic signaling
contributes to both positive and negative symptoms. This theory is supported by the psychotomimetic effects of NMDA
antagonists such as ketamine and PCP.
8. A PMHNP is educating a patient about how SSRIs work. Which explanation is most accurate?
A. "SSRIs increase the release of serotonin from presynaptic terminals."
B. "SSRIs block serotonin receptors postsynaptically to reduce anxiety."
C. "SSRIs block the reuptake of serotonin, increasing its availability in the synaptic cleft."
D. "SSRIs directly stimulate serotonin production in the raphe nuclei."
Rationale: SSRIs selectively inhibit the serotonin transporter (SERT), blocking reuptake of serotonin from the
synaptic cleft back into the presynaptic neuron. This increases serotonin availability at postsynaptic receptors. They
do not increase serotonin release, block postsynaptic receptors, or stimulate serotonin production.
2
, 9. Which neurotransmitter pathway, when blocked, results in elevated prolactin levels?
A. Nigrostriatal pathway
B. Mesolimbic pathway
C. Tuberoinfundibular pathway
D. Mesocortical pathway
Rationale: The tuberoinfundibular pathway normally exerts tonic dopaminergic inhibition on prolactin release from
the anterior pituitary. D2 receptor blockade in this pathway (by antipsychotics) removes this inhibition, leading to
hyperprolactinemia, which may cause galactorrhea, amenorrhea, and sexual dysfunction.
10. Acetylcholinesterase inhibitors are primarily used in the treatment of which condition?
A. Schizophrenia
B. Alzheimer's disease
C. Major depressive disorder
D. Bipolar disorder
Rationale: Acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) increase acetylcholine
availability in the brain by preventing its enzymatic breakdown. They are FDA-approved for symptomatic treatment of
Alzheimer's disease and are the mainstay of cognitive enhancement in dementia.
II. Pharmacokinetics & Pharmacodynamics (Questions 11-18)
11. A medication with a short half-life of 4 hours will reach steady-state concentration in approximately how
long?
A. 4 hours
B. 8 hours
C. 20 hours
D. 40 hours
Rationale: Steady-state concentration is achieved in approximately 4-5 half-lives. For a medication with a 4-hour
half-life, steady state is reached in 16-20 hours (4 x 4 = 16 to 5 x 4 = 20). This principle is critical for determining
when to assess therapeutic response and adjust dosing.
12. Which factor most significantly increases the bioavailability of a medication administered orally?
A. High first-pass metabolism
B. Administration with a high-fat meal
C. Extensive plasma protein binding
D. High water solubility
Rationale: Administration with a high-fat meal can increase the bioavailability of lipophilic medications by
enhancing their absorption through improved solubility in the gastrointestinal tract. First-pass metabolism
REDUCES bioavailability. Plasma protein binding affects distribution, not absorption. Water solubility alone does
not determine bioavailability.
13. A patient with hepatic cirrhosis is prescribed a psychotropic medication that undergoes extensive hepatic
metabolism. Which pharmacokinetic change is most expected?
A. Decreased volume of distribution
B. Increased clearance rate
3
